Lluís Pareras, from Invivo Ventures: 'Stopping now would be a mistake'

by Invivo Capital

Stopping now would be a mistake, because science and biotechnology will play a huge role in society and, for those who don’t stop now, having the advantage of these 2 quarters will be key. It is tim...

Read more

CAF, nuevo inversor en el Fondo de capital riesgo CRB Bio II, con una aportación de 3,9 millones

by CRB Health Tech

CAF compromete el 11,5% de las participaciones en el total de capital gestionado por el fondo, que ya ha invertido en siete compañías de diagnóstico de enfermedades neurodegenerativas y cardiovascu...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Alantra advises Precinmac on its acquisi...

by Alantra

This transaction reinforces Alantra’s continued momentum in Aerospac...

Photos Stream